Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity
about
Hormonal contraceptives for contraception in overweight or obese womenHormonal contraceptives for contraception in overweight or obese womenHormonal contraceptives for contraception in overweight or obese womenHormonal contraceptives for contraception in overweight or obese womenRationale for eliminating the hormone-free interval in modern oral contraceptivesMetabolic effects of contraceptive steroidsEffect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.Antimullerian hormone and obesity: insights in oral contraceptive users.Obesity and hormonal contraceptive efficacy.Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.Pharmacologic sex hormones in pregnancy in relation to offspring obesity.Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.Alteration of hepatic but not renal transporter expression in diet-induced obese miceA case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium.Hormonal contraceptive use before and after conception in relation to preterm birth and small for gestational age: an observational cohort study.Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic ReviewHow can we improve oral contraceptive success in obese women?Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.Obesity and oral contraceptive pill failure.Contraception and the obese woman.Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosingThe creeping Pearl: Why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?Effect of a combined estrogen and progesterone oral contraceptive on circulating adipocytokines adiponectin, resistin and DLK-1 in normal and obese female rhesus monkeys.Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.Impact of obesity on gynecology.Hormonal contraception in women with the metabolic syndrome: a narrative review.Safety and efficacy of contraception--Why should the obese woman be any different?Implications of obesity for drug therapy: limitations and challenges.European society of contraception statement on contraception in obese women.Perspectives on variability in pharmacokinetics of an oral contraceptive product.Clarification of contraceptive drug pharmacokinetics in obesity.Maternal obesity and pre-pregnancy folic acid supplementation.Safety of hormonal contraception for obese women.Levonorgestrel butanoate intramuscular injection does not reliably suppress ovulation for 90 days in obese and normal-BMI women: a pilot study.Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.Current Resources for Evidence-Based Practice, March/April 2017.
P2860
Q24197670-6C6AEF8E-1C83-421F-A04B-725C34BEA033Q24234234-BA9A5276-6E1F-42AC-ADDF-ACE734D8C44FQ24236450-07704CB0-4197-4F0D-A227-CE25228A95A0Q26470396-DCC45CF3-0133-401D-AAF1-43455CA067E8Q26749300-FFA34432-7146-46A0-9661-7CD76E4C132DQ28236638-6171A156-E208-4D88-9191-09CB1BB61836Q33570726-219EF031-272F-46E7-9651-433667E61744Q33669042-3DDB5563-EB8C-41BF-AD2A-67043E9F2712Q33836949-B6E0D8FE-5735-405E-868F-2F88EC6E5C33Q34266525-C4D020F6-39FE-43C9-947D-FFDC62CB36ABQ34401888-F291BF05-D9EA-43F2-8C2B-7F0E9DBA4E68Q34718314-A4567452-AABA-4C5C-875A-037D65AC7346Q35002476-77AC6E46-DB50-4F79-8932-535C015D616DQ35174900-AC1330C2-D86B-4F49-872A-F5963BA36502Q35449176-A5427A5E-29D8-4F2F-8C12-7EBC405E52BDQ35828378-B94C36C6-CD2C-4058-B201-0C3F892F15CCQ36089185-9A3D0374-1EDA-4E1C-A0F5-62B492B23D90Q36467300-8D4953CC-F228-4659-AB27-B8AF2AAB8A5DQ36800659-2ACF3B01-0A93-4564-986C-DFC2E49D5252Q36887471-4D35F99A-08E6-42F0-B0CE-5F41AD250C4BQ37094764-E174FF64-4D1D-4A84-B607-5FB545EDD86CQ37227518-D58B07E8-D583-45AF-B853-B157625439B9Q37575174-6E48C61E-CBDA-494B-80C9-10C4DCAA705EQ37586854-6C1067CA-45EA-4A66-AC37-E0F6916B988CQ37678420-70CA3F7E-6FC8-4E7C-B0A8-5BE586BA8F3EQ37778835-79C00D4F-A06B-4C1D-8C2D-0E7843CA337FQ37878974-E323B9DC-36DD-4740-BCA0-173A32E59A29Q37883897-25E19762-8488-414A-BE0E-4DEF291B413DQ38266121-F0618884-955D-4D16-B0AB-3BFC0434772EQ38913410-6DF6D761-9B93-495E-9387-7A51FA400B26Q38932206-17B1407F-0B69-4595-8B99-7B45F2E8622CQ49400922-507383DB-4383-4D89-8C06-B3ABF2909038Q49499945-C2A0ACAC-EBBA-4568-8CA2-BBCB57E9961EQ49549651-06FF87CF-1D4B-4BFF-94CA-C38DF7CB9C08Q53228207-E6ECCF97-CFF8-4641-BED4-915623182F3EQ53724208-9D4FBDCF-BDC3-4EFB-BAE6-AC35BBF4E40D
P2860
Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of obesity on oral cont ...... mic-pituitary-ovarian activity
@en
Impact of obesity on oral cont ...... ic-pituitary-ovarian activity.
@nl
type
label
Impact of obesity on oral cont ...... mic-pituitary-ovarian activity
@en
Impact of obesity on oral cont ...... ic-pituitary-ovarian activity.
@nl
prefLabel
Impact of obesity on oral cont ...... mic-pituitary-ovarian activity
@en
Impact of obesity on oral cont ...... ic-pituitary-ovarian activity.
@nl
P2093
P2860
P1433
P1476
Impact of obesity on oral cont ...... mic-pituitary-ovarian activity
@en
P2093
Alison B Edelman
Frank Z Stanczyk
Judy L Cameron
Myrna Y Munar
Nichole E Carlson
Richard L Stouffer
P2860
P304
P356
10.1016/J.CONTRACEPTION.2009.04.011
P577
2009-06-04T00:00:00Z